{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:06:38Z","timestamp":1792069598103,"version":"4.4.0"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.00859","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T01:03:58Z","timestamp":1565053438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":111,"title":["Gangliosides: Treatment Avenues in Neurodegenerative Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Pierre J.","family":"Magistretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred H.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Andy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Fiumelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Sipione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-8552-4_2","article-title":"Gangliosides of the nervous system","volume":"1804","author":"Ledeen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B2","first-page":"113","article-title":"Chapter Three\u2014The Biology of Gangliosides","volume-title":"Advances in Carbohydrate Chemistry and Biochemistry.","author":"Schnaar","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1152\/physrev.00033.2013","article-title":"Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration","volume":"94","author":"Schnaar","year":"2014","journal-title":"Physiol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/brain\/120.7.1123","article-title":"Exogenous gangliosides and Guillain-Barre syndrome. An observational study in the local health district of Ferrara, Italy","volume":"120","author":"Govoni","year":"1997","journal-title":"Brain."},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0022-510X(03)00215-6","article-title":"Is there a decrease in Guillain-Barre syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy","volume":"216","author":"Govoni","year":"2003","journal-title":"J Neurol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0165-5728(92)90033-H","article-title":"Effect of parenteral administration of GM1 on cytokines and anti-ganglioside antibody patterns. Preliminary report in normal human individuals","volume":"36","author":"Gallo","year":"1992","journal-title":"J Neuroimmunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1212\/WNL.45.6.1149","article-title":"GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy","volume":"45","author":"Schneider","year":"1995","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/cbic.201600705","article-title":"Gangliosides: structures, biosynthesis, analysis, and roles in cancer","volume":"18","author":"Groux-Degroote","year":"2017","journal-title":"Chembiochem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10719-013-9516-4","article-title":"GM3 and diabetes","volume":"31","author":"Inokuchi","year":"2014","journal-title":"Glycoconj J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1017\/S0007114507832946","article-title":"The role of dietary gangliosides on immunity and the prevention of infection","volume":"98","author":"Rueda","year":"2007","journal-title":"Br J Nutr."},{"key":"B11","first-page":"S507","article-title":"Monosialogangliosides, neuroprotection, and neuronal repair processes","volume":"9","author":"Skaper","year":"1992","journal-title":"J Neurotrauma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.3390\/nu7053891","article-title":"The role of gangliosides in neurodevelopment","volume":"7","author":"Palmano","year":"2015","journal-title":"Nutrients"},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmbts.2018.01.001","article-title":"Congenital disorders of ganglioside biosynthesis","volume":"156","author":"Li","year":"2018","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ng1460","article-title":"Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase","volume":"36","author":"Simpson","year":"2004","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajhg.2013.05.006","article-title":"Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia","volume":"93","author":"Boukhris","year":"2013","journal-title":"Am J Hum Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/brain\/awt270","article-title":"Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis","volume":"136","author":"Harlalka","year":"2013","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1001\/archneur.1991.00530220048018","article-title":"Gangliosides in cerebrospinal fluid in \u2018probable Alzheimer's disease'","volume":"48","author":"Blennow","year":"1991","journal-title":"Arch Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/BF03324111","article-title":"Differences in cerebrospinal fluid gangliosides between probable Alzheimer's disease and normal aging","volume":"4","author":"Blennow","year":"1992","journal-title":"Aging"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jnr.23090","article-title":"Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans","volume":"90","author":"Wu","year":"2012","journal-title":"J Neurosci Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1523\/JNEUROSCI.6348-09.2010","article-title":"Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1","volume":"30","author":"Maglione","year":"2010","journal-title":"J Neurosci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nbd.2007.05.003","article-title":"Glycolipid and ganglioside metabolism imbalances in Huntington's disease","volume":"27","author":"Desplats","year":"2007","journal-title":"Neurobiol Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/A:1011027125744","article-title":"Serum ganglioside patterns in multiple sclerosis","volume":"26","author":"Zaprianova","year":"2001","journal-title":"Neurochem Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF03159923","article-title":"Glycosphingolipids in the cerebrospinal fluid of patients with multiple sclerosis","volume":"13","author":"Miyatani","year":"1990","journal-title":"Mol Chem Neuropathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8100","DOI":"10.1073\/pnas.1508767112","article-title":"Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis","volume":"112","author":"Dodge","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ddr.430150402","article-title":"Gangliosides in treatment of neural injury and disease","volume":"15","author":"Mahadik","year":"1988","journal-title":"Drug Dev Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"41269","DOI":"10.1038\/srep41269","article-title":"Restoring GM1 ganglioside expression ameliorates axonal outgrowth inhibition and cognitive impairments induced by blast traumatic brain injury","volume":"7","author":"Rubovitch","year":"2017","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1046\/j.1471-4159.1998.70041335.x","article-title":"GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems","volume":"70","author":"Hadjiconstantinou","year":"1998","journal-title":"J Neurochem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/jnc.12760","article-title":"GM1 ganglioside enhances Ret signaling in striatum","volume":"130","author":"Newburn","year":"2014","journal-title":"J Neurochem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tibs.2015.04.005","article-title":"The multi-tasked life of GM1 ganglioside, a true factotum of nature","volume":"40","author":"Ledeen","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00018-005-5188-y","article-title":"Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins","volume":"62","author":"Mocchetti","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"B31","first-page":"93","article-title":"Prevention of neuronal apoptotic death by neurotrophic agents and ganglioside GM1: insights and speculations regarding a common mechanism","volume":"3","author":"Ferrari","year":"1996","journal-title":"Perspect Dev Neurobiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"49466","DOI":"10.1074\/jbc.M203240200","article-title":"Gangliosides activate Trk receptors by inducing the release of neurotrophins","volume":"277","author":"Rabin","year":"2002","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jnc.14146","article-title":"Role of the GM1 ganglioside oligosaccharide portion in the TrkA-dependent neurite sprouting in neuroblastoma cells","volume":"143","author":"Chiricozzi","year":"2017","journal-title":"J Neurochem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0006-3223(01)01123-4","article-title":"Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently","volume":"50","author":"Saxena","year":"2001","journal-title":"Biol Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10571-017-0510-4","article-title":"BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity","volume":"38","author":"Kowianski","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e907","DOI":"10.1038\/tp.2016.186","article-title":"Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease","volume":"6","author":"Jiao","year":"2016","journal-title":"Transl Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.neuropharm.2010.10.012","article-title":"Exogenous gangliosides increase the release of brain-derived neurotrophic factor","volume":"60","author":"Lim","year":"2011","journal-title":"Neuropharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0304-3940(93)90820-B","article-title":"Ganglioside GM1 cooperates with brain-derived neurotrophic factor to protect dopaminergic neurons from 6-hydroxydopamine-induced degeneration","volume":"159","author":"Fadda","year":"1993","journal-title":"Neurosci Lett"},{"key":"B39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.14670\/HH-25.237","article-title":"BDNF function and intracellular signaling in neurons","volume":"25","author":"Numakawa","year":"2010","journal-title":"Histol Histopathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"28587","DOI":"10.1074\/jbc.M110.125740","article-title":"Regulation of dendritic development by BDNF requires activation of CRTC1 by glutamate","volume":"285","author":"Finsterwald","year":"2010","journal-title":"J Biol Chem"},{"key":"B41","article-title":"Effects of GM1 on activation of signaling pathways in neurons and astrocytes, dependence of astrocyte-neuron interactions","volume-title":"Society for Neuroscience Meeting, abstract 211.23","author":"Fiumelli","year":"2016"},{"key":"B42","doi-asserted-by":"publisher","first-page":"255935","DOI":"10.1101\/255935","article-title":"Visualizing BDNF cell-to-cell transfer reveals astrocytes are the primary recipient of neuronal BDNF","author":"Stahlberg","year":"2018","journal-title":"bioRxiv"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1038\/tp.2013.30","article-title":"BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities","volume":"3","author":"Quesseveur","year":"2013","journal-title":"Transl Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1471-4159.2007.04722.x","article-title":"GM1 in the nuclear envelope regulates nuclear calcium through association with a nuclear sodium-calcium exchanger","volume":"103","author":"Ledeen","year":"2007","journal-title":"J Neurochem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0014-5793(99)01024-8","article-title":"Antagonistic effect of ganglioside GM1 and GM3 on the activity and conformation of sarcoplasmic reticulum Ca(2+)-ATPase","volume":"457","author":"Wang","year":"1999","journal-title":"FEBS Lett"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1046\/j.1471-4159.2002.00917.x","article-title":"Potentiation of a sodium-calcium exchanger in the nuclear envelope by nuclear GM1 ganglioside","volume":"81","author":"Xie","year":"2002","journal-title":"J Neurochem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"13246","DOI":"10.1523\/JNEUROSCI.1149-14.2014","article-title":"Ganglioside regulation of AMPA receptor trafficking","volume":"34","author":"Prendergast","year":"2014","journal-title":"J Neurosci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibs.2015.03.007","article-title":"Gangliosides: glycosphingolipids essential for normal neural development and function","volume":"40","author":"Schengrund","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.copbio.2012.09.004","article-title":"Transcriptome analysis using next-generation sequencing","volume":"24","author":"Mutz","year":"2013","journal-title":"Curr Opin Biotechnol"},{"key":"B50","unstructured":"National Spinal Cord Injury Statistical Center, Facts and Figures at a Glance.2016"},{"key":"B51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/CLEP.S68889","article-title":"Global prevalence and incidence of traumatic spinal cord injury","volume":"6","author":"Singh","year":"2014","journal-title":"Clin Epidemiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1017\/S0317167100014530","article-title":"Global incidence and prevalence of traumatic spinal cord injury","volume":"40","author":"Furlan","year":"2013","journal-title":"Can J Neurol Sci"},{"key":"B53","unstructured":"Spinal Cord Injury2013"},{"key":"B54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/sj.sc.3100501","article-title":"Causes and costs of spinal cord injury in the United States","volume":"35","author":"DeVivo","year":"1997","journal-title":"Spinal Cord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/BSD.0000000000000287","article-title":"Acute spinal cord injury","volume":"28","author":"Witiw","year":"2015","journal-title":"J Spinal Disord Tech"},{"key":"B56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2015.08.060","article-title":"Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury","volume":"219","author":"Kabu","year":"2015","journal-title":"J Control Release"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","article-title":"A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study","volume":"322","author":"Bracken","year":"1990","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/jama.1997.03540440031029","article-title":"Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial national acute spinal cord injury study","volume":"277","author":"Bracken","year":"1997","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00002517-200006000-00001","article-title":"A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury","volume":"13","author":"Coleman","year":"2000","journal-title":"J Spinal Disord"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1097\/TA.0b013e3181744b03","article-title":"Advanced trauma life support, 8th edition, the evidence for change","volume":"64","author":"Kortbeek","year":"2008","journal-title":"J Trauma"},{"key":"B61","doi-asserted-by":"publisher","first-page":"CD001046","DOI":"10.1002\/14651858.CD001046","article-title":"Steroids for acute spinal cord injury","volume":"1","author":"Bracken","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"CD001046","DOI":"10.1002\/14651858.CD001046.pub2","article-title":"Steroids for acute spinal cord injury","volume":"1","author":"Bracken","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/S0140-6736(05)66552-X","article-title":"Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months","volume":"365","author":"Edwards","year":"2005","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1227\/01.neu.0000430319.32247.7f","article-title":"Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update","volume":"60","author":"Walters","year":"2013","journal-title":"Neurosurgery."},{"key":"B65","first-page":"407","article-title":"Guidelines for the management of acute cervical spine and spinal cord injuries","volume":"49","author":"Hadley","year":"2002","journal-title":"Clin Neurosurg"},{"key":"B66","doi-asserted-by":"publisher","first-page":"E752","DOI":"10.1227\/NEU.0b013e318276ed9a","article-title":"Guidelines for GM-1 ganglioside in acute spinal cord injury","volume":"73","author":"Walters","year":"2013","journal-title":"Neurosurgery"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJM199112053252321","article-title":"Correction: recovery of motor function after spinal-cord injury\u2013a randomized, placebo-controlled trial with GM-1 ganglioside","volume":"325","author":"Geisler","year":"1991","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1056\/NEJM199106273242601","article-title":"Recovery of motor function after spinal-cord injury\u2013a randomized, placebo-controlled trial with GM-1 ganglioside","volume":"324","author":"Geisler","year":"1991","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1097\/00007632-200112151-00015","article-title":"The Sygen multicenter acute spinal cord injury study","volume":"26","author":"Geisler","year":"2001","journal-title":"Spine."},{"key":"B70","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1097\/00007632-200112151-00013","article-title":"Recruitment and early treatment in a multicenter study of acute spinal cord injury","volume":"26","author":"Geisler","year":"2001","journal-title":"Spine."},{"key":"B71","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1097\/00007632-200112151-00014","article-title":"Measurements and recovery patterns in a multicenter study of acute spinal cord injury","volume":"26","author":"Geisler","year":"2001","journal-title":"Spine."},{"key":"B72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/0304-3940(93)90287-U","article-title":"GM-1 ganglioside administration combined with physical therapy restores ambulation in humans with chronic spinal cord injury","volume":"161","author":"Walker","year":"1993","journal-title":"Neurosci Lett"},{"key":"B73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1161\/01.STR.22.1.22","article-title":"Monosialoganglioside in subarachnoid hemorrhage","volume":"22","author":"Papo","year":"1991","journal-title":"Stroke"},{"key":"B74","first-page":"595","article-title":"Efficacy and safety of ganglioside GM1 treatment in the rehabilitation of patients following closed traumatic head injury. Results of an interim evaluation","volume-title":"New Trends in Ganglioside Research: Neurochemical and Neuroregenerative Aspects (FIDIA Research Series)","author":"Hoermann","year":"1988"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1161\/01.STR.25.8.1552","article-title":"Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial","volume":"25","author":"Lenzi","year":"1994","journal-title":"Stroke"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1161\/01.STR.20.9.1143","article-title":"GM1 ganglioside therapy in acute ischemic stroke. Italian acute stroke study\u2013hemodilution + drug","volume":"20","author":"Argentino","year":"1989","journal-title":"Stroke"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/01.STR.25.6.1141","article-title":"Ganglioside GM1 in acute ischemic stroke. The SASS trial","volume":"25","author":"Alter","year":"1994","journal-title":"Stroke"},{"key":"B78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-3-642-76208-6_54","article-title":"GM1 Ganglioside therapy in acute ischemic stroke","volume-title":"Cerebral Ischemia and Dementia","author":"Scarpino","year":"1991"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/jnnp.51.9.1213","article-title":"Trial of ganglioside GM1 in acute stroke","volume":"51","author":"Hoffbrand","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B80","article-title":"Wirksamkeit und Vertr\u00e4glichkeit von GM1-Fidia bei Patienten mit Hirninfarkt (Effectiveness and Tolerance of GM1 (Fidia) in Patients With Apoplexy)","author":"Reuther","year":"1989"},{"key":"B81","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000115823","article-title":"Effects of GM1 ganglioside in cerebrovascular diseases: a double-blind trial in 40 cases","volume":"24","author":"Battistin","year":"1985","journal-title":"Eur Neurol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jnr.490120232","article-title":"Double-blind evaluation of monosialoganglioside (GM1) therapy in stroke","volume":"12","author":"Bassi","year":"1984","journal-title":"J Neurosci Res"},{"key":"B83","article-title":"Monosialotetraesosilganglioside: Studio Dell'efficacia Clinica e della Tollerabilit\u00e1 in Pazienti Affetti da Vasculopatia Cerebrale Acuta su base Ischemica o Emorragica (Monosialoganglioside: Study of Clinical Efficacy and Tolerance in Patients Affected by Acute Cerebrovascular Disorders of Ischemic or Hemorrhagic Origin)","author":"Frattola","year":"1983"},{"key":"B84","volume-title":"Monosialotetraesosilganglioside: Studio Dell'efficacia Clinica e Della Tollerabilit\u00e0 in Pazienti Affetti da Patologia Cerebrovascolare Acuta Su Base Ischemica ed Emorragica (Monosialoganglioside: Study of Clinical Efficacy and Tolerance IN Patients Affected by Acute Cerebrovascular Disorders of Ischemic or Hemorrhagic Origin).","author":"D'Agnini","year":"1983"},{"key":"B85","first-page":"S602","article-title":"The effect of ganglioside (GM1) treatment in acute ischemic infarction: a positron emission tomography study","volume":"9","author":"Jamieson","year":"1989","journal-title":"J Cereb Blood Flow Metab"},{"key":"B86","first-page":"433ff","article-title":"Effects of gangliosides upon rehabilitation of patients following stroke","volume-title":"Pharmacology of Cerebral Ischemia","author":"Heiss","year":"1988"},{"key":"B87","article-title":"Trattamento precoce con monosialoganglioside GM1 nella fase acuta degli accidenti cerebrovascolari (Early treatment with monosialoganglioside GM1 in the acute phase of stroke)","volume-title":"Abstract Presented at The XLIII National Congress","author":"De Blasio","year":"1989"},{"key":"B88","volume-title":"Clinical Trial of GM1 in Patients Following Cerebrovascular Accidents","author":"Abraham","year":"1986"},{"key":"B89","doi-asserted-by":"publisher","first-page":"H2442","DOI":"10.1152\/ajpheart.01169.2003","article-title":"Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury","volume":"286","author":"Kusaka","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.brainres.2010.05.044","article-title":"Monosialotetrahexosy-1 ganglioside attenuates diabetes-enhanced brain damage after transient forebrain ischemia and suppresses phosphorylation of ERK1\/2 in the rat brain","volume":"1344","author":"Zhang","year":"2010","journal-title":"Brain Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jocn.2017.03.047","article-title":"Monosialotetrahexosy-1 ganglioside attenuates diabetes-associated cerebral ischemia\/reperfusion injury through suppression of the endoplasmic reticulum stress-induced apoptosis","volume":"41","author":"Su","year":"2017","journal-title":"J Clin Neurosci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/nbdi.2000.0363","article-title":"Phosphorylation of extracellular signal-regulated kinase after transient cerebral ischemia in hyperglycemic rats","volume":"8","author":"Li","year":"2001","journal-title":"Neurobiol Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1179\/1743132811Y.0000000015","article-title":"Augmentation of endoplasmic reticulum stress in cerebral ischemia\/reperfusion injury associated with comorbid type 2 diabetes","volume":"33","author":"Srinivasan","year":"2011","journal-title":"Neurol Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.7150\/ijbs.15624","article-title":"Rapamycin reduced ischemic brain damage in diabetic animals is associated with suppressions of mTOR and ERK1\/2 signaling","volume":"12","author":"Liu","year":"2016","journal-title":"Int J Biol Sci"},{"key":"B95","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lfs.2011.10.017","article-title":"3-Bromo-7-nitroindazole attenuates brain ischemic injury in diabetic stroke via inhibition of endoplasmic reticulum stress pathway involving CHOP","volume":"90","author":"Srinivasan","year":"2012","journal-title":"Life Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbr.2011.07.004","article-title":"Sodium phenylbutyrate ameliorates focal cerebral ischemic\/reperfusion injury associated with comorbid type 2 diabetes by reducing endoplasmic reticulum stress and DNA fragmentation","volume":"225","author":"Srinivasan","year":"2011","journal-title":"Behav Brain Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J Neural Transm"},{"key":"B98","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","article-title":"Epidemiology of Parkinson's disease","volume":"172","author":"Elbaz","year":"2016","journal-title":"Rev Neurol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0959-440X(02)00376-7","article-title":"Lubricating cell signaling pathways with gangliosides","volume":"12","author":"Allende","year":"2002","journal-title":"Curr Opin Struct Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1042\/BC20060051","article-title":"Lipid rafts in health and disease","volume":"99","author":"Michel","year":"2007","journal-title":"Biol Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1021\/bi061749a","article-title":"GM1 specifically interacts with alpha-synuclein and inhibits fibrillation","volume":"46","author":"Martinez","year":"2007","journal-title":"Biochemistry"},{"key":"B103","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0006-8993(94)91886-4","article-title":"GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment","volume":"640","author":"Stull","year":"1994","journal-title":"Brain Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0014-4886(89)90117-9","article-title":"GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism","volume":"105","author":"Schneider","year":"1989","journal-title":"Exp Neurol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1350379","article-title":"Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment","volume":"256","author":"Schneider","year":"1992","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/WNL.50.6.1630","article-title":"Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study","volume":"50","author":"Schneider","year":"1998","journal-title":"Neurology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jns.2012.10.024","article-title":"A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients","volume":"324","author":"Schneider","year":"2013","journal-title":"J Neurol Sci"},{"key":"B108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2010.02.009","article-title":"GM1 ganglioside in Parkinson's disease: results of a five year open study","volume":"292","author":"Schneider","year":"2010","journal-title":"J Neurol Sci"},{"key":"B109","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington's disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B111","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: the Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B112","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"B114","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-444-63233-3.00017-8","article-title":"Huntington disease","volume":"147","author":"Ghosh","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1471-4159.2010.06964.x","article-title":"Cerebellar lipid differences between R6\/1 transgenic mice and humans with Huntington's disease","volume":"115","author":"Denny","year":"2010","journal-title":"J Neurochem"},{"key":"B116","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1073\/pnas.1114502109","article-title":"Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice","volume":"109","author":"Di Pardo","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.15252\/emmm.201707763","article-title":"Disease-modifying effects of ganglioside GM1 in Huntington's disease models","volume":"9","author":"Alpaugh","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/hbm.22612","article-title":"The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study","volume":"36","author":"Sanchez-Castaneda","year":"2015","journal-title":"Hum Brain Mapp"},{"key":"B122","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/jnc.12739","article-title":"Iron dysregulation in Huntington's disease","volume":"130","author":"Muller","year":"2014","journal-title":"J Neurochem"},{"key":"B123","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0896-6273(00)80798-9","article-title":"Beyond the dopamine receptor: the DARPP-32\/protein phosphatase-1 cascade","volume":"23","author":"Greengard","year":"1999","journal-title":"Neuron"},{"key":"B124","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.pharmtox.44.101802.121415","article-title":"DARPP-32: an integrator of neurotransmission","volume":"44","author":"Svenningsson","year":"2004","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"J Cell Biol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nchembio.582","article-title":"Kinase inhibitors modulate huntingtin cell localization and toxicity","volume":"7","author":"Atwal","year":"2011","journal-title":"Nat Chem Biol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.febslet.2009.12.010","article-title":"Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction","volume":"584","author":"Posse de Chaves","year":"2010","journal-title":"FEBS Lett."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"B130","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2018.09.022","article-title":"Huntington disease: a quarter century of progress since the gene discovery","volume":"396","author":"Testa","year":"2018","journal-title":"J Neurol Sci"},{"key":"B131","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrd.2018.133","article-title":"Therapeutic approaches to Huntington disease: from the bench to the clinic","volume":"17","author":"Caron","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B132","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/nat.2018.0720","article-title":"Dose-dependent lowering of mutant Huntingtin using antisense oligonucleotides in Huntington disease patients","volume":"28","author":"van","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"B133","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/0024-3205(94)00393-9","article-title":"Gangliosides\u2013a new therapeutic agent against stroke and Alzheimer's disease","volume":"55","author":"Svennerholm","year":"1994","journal-title":"Life Sci"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.2174\/138161208786404137","article-title":"Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease","volume":"14","author":"Yamin","year":"2008","journal-title":"Curr Pharm Des"},{"key":"B136","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1176\/ajp.151.1.126","article-title":"A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease","volume":"151","author":"Flicker","year":"1994","journal-title":"Am J Psychiatry"},{"key":"B137","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000063604","article-title":"Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme","volume":"14","author":"Svennerholm","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"B138","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10719-015-9579-5","article-title":"GM1 ganglioside and Alzheimer's disease","volume":"32","author":"Yanagisawa","year":"2015","journal-title":"Glycoconj J"},{"key":"B139","doi-asserted-by":"publisher","first-page":"9411","DOI":"10.1002\/anie.201603178","article-title":"GM1 ganglioside inhibits \u03b2-amyloid oligomerization induced by sphingomyelin","volume":"55","author":"Amaro","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"B140","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1471-4159.2007.05128.x","article-title":"Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation","volume":"105","author":"Yuyama","year":"2008","journal-title":"J Neurochem"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.bbamem.2008.07.028","article-title":"Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis","volume":"1778","author":"Yamamoto","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.neurobiolaging.2007.12.022","article-title":"Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice","volume":"30","author":"Bernardo","year":"2009","journal-title":"Neurobiol Aging"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s10072-012-1263-y","article-title":"Monosialoanglioside improves memory deficits and relieves oxidative stress in the hippocampus of rat model of Alzheimer's disease","volume":"34","author":"Yang","year":"2013","journal-title":"Neurol Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1194\/jlr.R800007-JLR200","article-title":"Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease\u2013a review","volume":"49","author":"Ariga","year":"2008","journal-title":"J Lipid Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s11064-017-2266-0","article-title":"Enhanced autophagy contributes to protective effects of GM1 ganglioside against A\u03b21-42-induced neurotoxicity and cognitive deficits","volume":"42","author":"Dai","year":"2017","journal-title":"Neurochem Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"24488","DOI":"10.1074\/jbc.M114.577213","article-title":"Decreased amyloid-\u03b2 pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice","volume":"289","author":"Yuyama","year":"2014","journal-title":"J Biol Chem"},{"key":"B147","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/0306-4522(93)90142-3","article-title":"GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys","volume":"56","author":"Herrero","year":"1993","journal-title":"Neuroscience"},{"key":"B148","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1749-6632.1998.tb09680.x","article-title":"Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice","volume":"845","author":"Rothblat","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"B149","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jns.2015.06.028","article-title":"GM1 ganglioside in Parkinson's disease: pilot study of effects on dopamine transporter binding","volume":"356","author":"Schneider","year":"2015","journal-title":"J Neurol Sci"},{"key":"B150","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF03160083","article-title":"Brain content of glycosphingolipids after oral administration of monosialogangliosides GM1 and LIGA20 to rats","volume":"21","author":"Polo","year":"1994","journal-title":"Mol Chem Neuropathol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/jnr.490370310","article-title":"Differential accumulation of gangliosides by the brains of MPTP-lesioned mice","volume":"37","author":"Saulino","year":"1994","journal-title":"J Neurosci Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1042\/bj2370147","article-title":"Incorporation and metabolism of exogenous GM1 ganglioside in rat liver","volume":"237","author":"Ghidoni","year":"1986","journal-title":"Biochem J"},{"key":"B153","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-0404.1990.tb00930.x","article-title":"Parenteral administration of GM1 ganglioside to presenile Alzheimer patients","volume":"81","author":"Svennerholm","year":"1990","journal-title":"Acta Neurol Scand"},{"key":"B154","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0361-9230(90)90297-D","article-title":"The role(s) of gangliosides in neural differentiation and repair: a perspective","volume":"24","author":"Schengrund","year":"1990","journal-title":"Brain Res Bull"},{"key":"B155","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mus.880130910","article-title":"Critical review of gangliosides and thyrotropin-releasing hormone in peripheral neuromuscular diseases","volume":"13","author":"Bradley","year":"1990","journal-title":"Muscle Nerve"},{"key":"B156","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1213\/00000539-199309000-00015","article-title":"Neurotoxicology of chronic infusion of the ganglioside GM1 in the ewe: phase I. intrathecal administration","volume":"77","author":"Coombs","year":"1993","journal-title":"Anesth Analg"},{"key":"B157","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/dmd.108.024745","article-title":"Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport","volume":"37","author":"Syvanen","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/mp300570z","article-title":"Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states","volume":"10","author":"Deo","year":"2013","journal-title":"Mol Pharm"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T01:04:09Z","timestamp":1565053449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":158,"alternative-id":["10.3389\/fneur.2019.00859"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.00859","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"article-number":"859"}}